The research team, led by Knut Liepe of the Department of Nuclear Medicine at GH Hospital Klinikum Frankfurt (Oder) in Germany, together with colleagues from Ruhr University Bochum’s Johannes Wesling Hospital Minden and independent collaborators, examined 91 patients who underwent primary staging with [99mTc]Tc-PSMA SPECT/CT. Each patient received a median administered activity of 670 megabecquerels of the radiotracer [99mTc]Tc-MIP-1404, with a range of 470 to 792 megabecquerels. The imaging technique fuses single-photon emission computed tomography, which maps the distribution of the radiolabelled prostate-specific membrane antigen ligand, with computed tomography, which provides anatomical context. Together, the two modalities allow physicians to visualise both the primary tumour within the prostate and any metastatic deposits in pelvic lymph nodes or distant organs.

PSMA—prostate-specific membrane antigen—is a transmembrane protein expressed abundantly and relatively homogeneously on the surface of prostate cancer cells, a biological property that has made it one of the most successful molecular imaging targets in oncology. Radiolabelled ligands such as MIP-1404 bind to PSMA, concentrating radiation signal at tumour sites and enabling detection of lesions that conventional bone scans and CT frequently miss. While PSMA PET/CT has become the reference standard for staging in high-income centres, guided by landmark randomised trials such as proPSMA, PET infrastructure is expensive, dependent on short-lived isotopes, and unevenly distributed globally. SPECT cameras, by contrast, are far more widespread, which is precisely why the German team’s analysis of when technetium-based PSMA SPECT/CT delivers meaningful diagnostic yield matters so much.

The core of the study is a statistical interrogation of how two pre-imaging variables interact to determine what the scan will find. Using univariate and multivariate nominal logistic regression, the investigators tested whether the initial PSA level (iPSA) and the International Society of Urological Pathology grade group—assigned from 1, the least aggressive, to 5, the most aggressive—predicted the presence of metastatic disease. Both emerged as independent predictors. The effect of PSA was the stronger of the two, with a p-value of 0.0004, while ISUP grade remained significant at p equal to 0.0015. In practical terms, a man’s blood test and his biopsy pathology, taken together, already encode much of the information the scanner will later confirm.

The detection-rate thresholds that emerged from the analysis are strikingly concrete. Detection rates of metastatic disease on [99mTc]Tc-PSMA SPECT/CT exceeded 50 percent in two patient subgroups: those with ISUP grades 1 to 3 whose initial PSA exceeded 50 nanograms per millilitre, and those with ISUP grades 4 to 5 whose initial PSA exceeded 20 nanograms per millilitre. Even more dramatically, metastases were detected in every single patient whose initial PSA was above 50 nanograms per millilitre, regardless of how indolent or aggressive the tumour appeared under the microscope. For clinicians weighing whether to order the scan, these cutoffs offer an evidence-based filter: below them, the probability of finding spread disease drops enough that the examination may not justify its cost and radiation exposure.

Beyond the headline thresholds, the study revealed that the two risk variables shape not just whether metastases appear but where they appear. Among patients with ISUP grades 1 to 3 across all PSA levels, and among those with ISUP grades 4 to 5 whose PSA was 20 nanograms per millilitre or below, pelvic lymph node metastases predominated—spread confined to the regional drainage basins around the prostate. In contrast, patients with ISUP grades 4 to 5 and initial PSA above 50 nanograms per millilitre were far more likely to harbour distant metastases, the true game-changers in treatment planning, since they shift management from curatively intended surgery or radiotherapy toward systemic therapy. The pattern echoes the biological logic of tumour progression: increasingly disorganised, high-grade tumours paired with heavy tumour burden, reflected in soaring PSA, are more capable of seeding far-flung sites.

The team also examined whether the scanner’s own quantitative output could substitute for pathology. The maximum standardised uptake value, SUVmax, which reflects the peak concentration of the radiotracer in the primary tumour, correlated strongly with ISUP grade, with a correlation coefficient of 0.61. Yet the authors caution that SUVmax was not a reliable surrogate marker for aggressiveness. The correlation, while robust statistically, is too loose to replace histopathological grading, whose tissue-based assessment captures architectural and nuclear features that tracer uptake only approximates. The finding is a reminder of a broader lesson in molecular imaging: quantitative biomarkers complement but do not supplant the pathologist’s verdict on biopsy material.

The implications reach well beyond the German centres where the data were collected. In the United States, Europe, and Australia, PSMA PET/CT is increasingly embedded in guidelines for high-risk disease, but in much of Asia, Africa, Latin America, and Eastern Europe, PET capacity remains a bottleneck. Technetium-99m, the isotope used in this study, is produced in widely distributed generator systems, requires no on-site cyclotron, and its SPECT cameras are already installed in thousands of nuclear medicine departments worldwide. When PSMA PET/CT is simply unavailable, the authors conclude, [99mTc]Tc-PSMA SPECT/CT may represent a valuable alternative for the primary staging of carefully selected prostate cancer patients—and the combined PSA-plus-ISUP criteria from this study supply exactly the selection logic that such an alternative needs to be used economically and effectively.

Of course, the study’s retrospective design and modest cohort of 91 patients mean the findings require prospective validation before they can be written into guidelines. Selection bias is possible, since the patients who received SPECT/CT may not represent the full spectrum of newly diagnosed disease, and detection thresholds derived from one tracer, one administered activity range, and one scanner generation may not transfer unchanged to other settings. The authors received no external funding for the work and declared relevant consultancy and lecture-fee relationships in the nuclear medicine industry. Still, the core message is likely to endure: the two numbers sitting at the top of every prostate cancer chart—the PSA value and the biopsy grade—together form a powerful pre-test probability engine. Used deliberately, they can direct PSMA imaging, whether by SPECT or PET, to the men most likely to benefit, sparing others an unnecessary scan while ensuring that metastatic disease, wherever it hides, is found before treatment plans are locked in.

Subject of Research: Patient selection criteria for primary staging of prostate cancer using [99mTc]Tc-PSMA SPECT/CT based on PSA level and ISUP grade

Article Title: Patient selection for primary staging with [99mTc]Tc-PSMA SPECT/CT: influence of combined PSA and ISUP grade on detection of metastatic disease

Article References: Liepe, K., Hoang, T. M., Dietrich, I., Piechota, H.-J., & Baehr, M. (2026). Patient selection for primary staging with [99mTc]Tc-PSMA SPECT/CT: influence of combined PSA and ISUP grade on detection of metastatic disease. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08168-8

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08168-8

Keywords: prostate cancer, PSMA SPECT/CT, PSA, ISUP grade, primary staging, metastatic disease, [99mTc]Tc-MIP-1404, SUVmax, pelvic lymph node metastases, nuclear medicine, patient selection, molecular imaging

The implications of these findings extend far into clinical practice, suggesting that oncologists might need to broaden their surveillance strategies. As prostate cancer patients often face the risk of metastases, particularly after treatments like surgery or radiation therapy, the discovery necessitates a reassessment of how thorough surveillance should be. The landmark paper not only uncovers the anatomical complexity of prostate cancer spread but also emphasizes the necessity for advanced imaging techniques that can better clarify the intricate pathways of malignancy.

In parallel, researchers have demonstrated a novel ultra-low-dose PET scanning method, which effectively produces high-resolution images in a notably shorter timeframe of 20–30 minutes. This innovative approach leverages long-axial-field-of-view technology combined with a CT-free correction technique, termed LSO-TX. By tapping into background radiation emitted from the scanner materials, this method significantly decreases patient radiation exposure while maintaining the quality of diagnostic images essential for identifying cancer and metabolic conditions. This advancement represents a significant leap in addressing patient safety while ensuring diagnostic accuracy in tumor evaluation.

Furthermore, the balance between minimizing radiation exposure and avoiding the degradation of image quality displays a pivotal concern in the field of nuclear medicine. Ensuring that imaging techniques evolve in a manner that adheres to safety regulations while still providing clinicians with the tools necessary to make informed decisions is crucial. As healthcare providers increasingly prioritize patient-centered care, these innovations underscore how modern imaging technology can result in better outcomes.

The relevance of capable imaging methodologies cannot be overstated, especially given the evolving nature of cancer treatments and the urgency to tailor approaches specific to individual patient profiles. By providing clearer insights into the behavior of cancer at a molecular level, these imaging technologies will facilitate more precise interventions, effectively aligning with the growing trend towards personalized medicine. The application of advanced imaging might also influence researchers and clinicians to investigate further correlation between specific imaging findings and patients’ prognoses, ultimately refining treatment pathways and improving life expectancy.

As medical science continues to advance, the findings presented in this research are critical for propelling the field of nuclear medicine forward. The dual discovery of both unexpected spread patterns in prostate cancer and a more effective imaging technique pave the way for enhanced clinical practices. The intersection of these findings suggests that further exploration into the metastatic behavior of prostate cancer, particularly within the testicular region, should be prioritized, as it represents a potential blind spot in traditional diagnostic practices.

In light of these discoveries, support for ongoing research initiatives is paramount. Stakeholders within the healthcare community, including clinicians, researchers, and professional organizations, should advocate for the continued development of such technologies. This advocacy will not only ensure advancements in clinical applications but also promote the overall health and well-being of patients navigating these complex cancer pathways.

Moreover, the significance of these findings extends beyond immediate clinical implications; they highlight the necessity for comprehensive education within the medical community. As new research unveils unprecedented data, it becomes essential for healthcare educators to disseminate this knowledge effectively, ensuring that current and future medical practitioners are equipped with the most up-to-date information. Engaging medical students and professionals in discussions around the transformative nature of imaging techniques is vital for fostering an informed and prepared healthcare workforce.

Ultimately, the revelations surrounding prostate cancer’s rare metastatic potential and the emergence of ultra-low-dose imaging techniques represent an extraordinary leap forward in nuclear medicine. As clinical providers adopt these methodologies into their practices, patients could anticipate a more nuanced approach to monitoring and treatment, thereby enhancing overall outcomes and life quality. The ongoing evolution in imaging technology signifies a promising horizon where prostate cancer care is not only informed by science but also driven by empathy and a commitment to patient wellness.

With these advancements, healthcare professionals remain hopeful that such innovations will lead to more effective monitoring and treatment strategies. The focus will remain squarely on patient safety and care quality, breeding confidence in the systems designed to combat one of the most challenging diseases of our time. In conclusion, the integration of these findings into standard clinical practice represents a call to action within the medical community for continued research and adaptation.

Subject of Research: Prostate cancer metastases and ultra-low-dose PET scanning
Article Title: Tracing Prostate Cancer Beyond the Usual Path
News Publication Date: April 11, 2025
Web References: JNM Website
References: SNMMI Media Center
Image Credits: N/A
Keywords: Prostate cancer, metastasis, PSMA PET/CT scans, imaging technology, nuclear medicine, personalized medicine, patient safety, cancer monitoring.